The analysis of efficacy of the use of inhibitor interleukin-1 in the complex therapy of secondary osteoarthritis taking into account the dynamics of clinical and functional indicators

Cover Page

Abstract


Backgraund: Secondary osteoarthritis (OA) adversely affects an underlying disease and can enhance clinical manifestations of articular syndrome. Early detection of comorbid pathology and early treatment with the therapy of underlying condition is of primary importance to preserve adequate functional activity in patients.

The Aims to analyze the efficacy of the use of inhibitor of interleukin -1 in the complex treatment of secondary OA in rheumatoid arthritis (RA).

Materials and methods: 248 patients with secondary OA in RA were divided in 4 groups: patients of group I (n=62) took inhibitor of interleukin-1 (50mg x 2 times per day) in combination with laser therapy on the basis of methotrexate (10-20 mg per week), group II (n=60) received inhibitor of interleukin-1 in complex with methotrexate, in group III (n=62)-laser therapy with methotrexate and in group 4 – methotrexate. The analysis of treatment efficacy we estimated in 3 and 6 months according to the dynamics of pain on VAS, indexes HAQ and KOOS.

Results: group 1 showed statistical significant reduction of pain on VAS on movement after 3 and 6 months on 28,53 mm (43,6%) and 31,3 мм (48%) accordingly, to values 36,87±1,56* и 33,11±1,11* (p<0,05). It was noted the statistical significant advantages of HAQ dynamics in group I in comparison with groups II, III, IV (p=0,03). The most prominent statistical significant (p=0,02) significant advantages according to the dynamics of index KOOS it was noted in groups of patients who took diacerein (I and II) after 6 months complex treatment.

Conclusions: the involvement of inhibitor of interleukin -1 in the complex treatment of secondary OA in patients with RA contributes to clinical improvement according to VAS (p=0,03), index KOOS, that shows functional condition of the knee and increase the quality of life by index HAQ (p=0,03) after 6 months therapy.


I. A. Starodubtseva

N.N. Burdenko Voronezh State Medical University, Voronezh

Author for correspondence.
Email: starodubtsevairina1@gmail.com

Russian Federation PhD, Postdoctoral Research Fellow Department of Internal Diseases

L. V. Vasilieva

N.N. Burdenko Voronezh State Medical University, Voronezh

Email: sia_1111@mail.ru

Russian Federation

MD, PhD, Professor, Head of Department on Internal Diseases

A. V. Nikitin

N.N. Burdenko Voronezh State Medical University, Voronezh

Email: sia_1111@mail.ru

Russian Federation

MD, PhD, Professor, Head of Department

  1. Kraus VB, Blanco FJ, Englund M, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis and Cartilage. 2015;23(8):1233-1241. doi: 10.1016/j.joca.2015.03.036.
  2. Rogers R, Shepstone L, Dieppe P. Is osteoarthritis a systemic disorder? Arthr Rheum. 2004;50:452–457. doi: 10.1002/art.20136.
  3. Гордеев А.В., Галушко Е.А., Насонов Е.Л. Концепция мультиморбидности в ревматологической практике // Научно-практическая ревматология. – 2014. – №4. – С. 362–365. [Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchno-prakticheskaya revmatologiya. 2014;52(4):362–365. (In Russ.)] doi: 10.14412/1995-4484-2014-362-365.
  4. Radner H, Yoshida K, Smolen JS, et al. Multimorbidity and rheumatic conditions-enhancing the concept of comorbidity. Nat Rev Rheumatology. 2014;10(4):252–256. doi: 10.1038/nrrheum.2013.212.
  5. Kinne S, Patrick DL, Doyle DL. Prevalence of secondary conditions among people with disabilities. Am J Publ Health. 2004;94(3):443– 445. doi: 10.2105/ajph.94.3.443.
  6. Loo FAJVD, Joosten LAB, Van Lent PLEM, et al. Role of interleukin-1, tumor necrosis factor alpha, and inerleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigenand zymosan induced arthritis. Arthr Rheum. 1995;38:164–172. doi: 10.1002/art.1780380204.
  7. Tamura T, Shirai T, Kosaka N. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur J Pharm. 2002;448:81–87. doi: 10.1016/s0014-2999(02)01898-8.
  8. Tamura T, Yokoyama T, Ohmori K. Effect of Diacerein on Indomethacin-induced gastric ulceration. Pharmacol. 2001;63:228–233. doi: 10.1159/000056138.
  9. P127 A systematic meta-analysis trials with Diacerein in osteoarthritis. Osteoarthritis and cartilage. 2005;(13 suppl. 1):68. doi: 10.1016/s1063-4584(05)80472-8.
  10. Наумов А.В. Эффективность и безопасность диацереина в терапии хронической боли при остеоартрите у пациентов с сердечно-сосудистой коморбидностью и противопоказаниями к НПВП // Поликлиника. – 2015. – №5(1). – С. 33–38. [Naumov AV. Effektivnost’ i bezopasnost’ diatsereina v terapii khronicheskoi boli pri osteoartrite u patsientov s serdechno-sosudistoi komorbidnost’yu i protivopokazaniyami k NPVP. Poliklinika. 2015;(5–1):33–38. (In Russ).]
  11. Ведение больных остеоартритом и коморбидностью в общей врачебной практике. Клинические рекомендации консенсуса экспертов РФ / Сост. Наумов А.В., Алексеева Л.И., Верткин А.Л. – М.; 2015. 36 с. [Vedenie bol’nykh osteoartritom i komorbidnost’yu v obshchei vrachebnoi praktike. Klinicheskie rekomendatsii konsensusa ekspertov RF. Ed by Naumov A.V., Alekseeva L.I., Vertkin A.L. Moscow; 2015. 36 p. (In Russ).]
  12. Мартынов А.И., Наумов А.В., Верткин А.Л. и др. Ведение больных остеоартритом с коморбидностью в общей врачебной практике: мнение экспертов, основанное на доказательной медицине // Лечащий врач. – 2015. – №4. – С. 39–46. [Martynov AI, Naumov AV, Vertkin AL, et al. Vedenie bol’nykh osteoartritom s komorbidnost’yu v obshchei vrachebnoi praktike: mnenie ekspertov, osnovannoe na dokazatel’noi meditsine. Lechashchii vrach. 2015;4:39–46. (In Russ).]
  13. Гейниц А.В., Москвин С.В., Ачилов А.А. Внутривенное лазерное облучение крови. – Тверь: Триада; 2008. 144 с. [Geinits AV, Moskvin SV, Achilov AA. Vnutrivennoe lazernoe obluchenie krovi. Tver: Triada; 2008. 144 p. (In Russ).]
  14. Бодрова РА. Локальная терапия суставного синдрома. Патогенетический подход к назначению аппликационной терапии и физических факторов. Учебно-методическое пособие. – Казань; 2005. 36 с. [Bodrova RA. Lokal’naya terapiya sustavnogo sindroma. Patogeneticheskii podkhod k naznacheniyu applikatsionnoi terapii i fizicheskikh faktorov. Uchebno-metodicheskoe posobie. Kazan; 2005. 36 p. (In Russ).]
  15. Буйлин В.А. Магнитолазерная терапия заболеваний суставов и позвоночника. – М.: Адвансед Солюшнз; 2011. 86 с. [Builin VA. Magnitolazernaya terapiya zabolevanii sustavov i pozvonochnika. Moscow: Advansed Solyushnz; 2011. 86 p. (In Russ).]
  16. Агаев Б.А., Гейниц А.В., Мамедов М.М. Руководство по эффективному использованию лазерных технологий в хирургии доброкачественной патологии печени и желчевыводящих путей. – Баку: Китаб алеми; 2010. 148 с. [Agaev BA, Geinits AV, Mamedov MM. Rukovodstvo po effektivnomu ispol’zovaniyu lazernykh tekhnologii v khirurgii dobrokachestvennoi patologii pecheni i zhelchevyvodyashchikh putei. Baku: Kitab alemi; 2010. 148 p. (In Russ).]
  17. Brosseau L, Welch V, Wells G, et al. Low level laser therapy for osteoarthritis and rheumatoid arthritis: a meta-analysis. J Rheumatol. 2000;27(8):1961–1969.
  18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 1988;31(3):315–324.
  19. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–1588. doi: 10.1136/ard.2010.138461.
  20. Restrictions of the use of diacerein containing medicines. Restrictions intended to limit risks of severe diarrhea and effects on the liver. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/European_Commission_final_decision/WC500173144.pdf (Accessed: 2014 Sept 15).
  21. Ревматология. Клинические рекомендации / Под ред. Насонова Е.Л. – М.: ГЭОТАР-Медиа; 2010. 752 с. [Rheumatology. Clinical guidelines. Ed by Nasonova E.L. Moscow: GEOTARMedia; 2010. 752 p. (In Russ).]
  22. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseases ― modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013;73(3):492–509. doi: 10.1136/annrheumdis-2013-204573.
  23. Smolen J, Aletaha D, Bijlsma J, et al. Treating rheumatoid arthritis to target: recommendation of an international task force. Ann Rheum Dis. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919.
  24. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standin Committee for International Clinical Studies, including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155. doi: 10.1136/ard.2003.011742.
  25. Орлов А.И. Прикладная статистика. Учебник для вузов. – М.: Экзамен; 2006. 672 с. [Orlov AI. Prikladnaya statistika. Uchebnik dlya vuzov. Moscow: Ekzamen; 2006. 672 p. (In Russ).]
  26. Феллер В. Введение в теорию вероятностей и ее приложения. Пер. с англ. – М.: Мир; 1984. Т.1−2. 1280 с. [Feller V. Vvedenie v teoriyu veroyatnostei i ee prilozheniya. Transl. Moscow: Mir; 1984. Vol.1−2. 1280 p. (In Russ).]
  27. Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of Diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three month treatment period. Arthr Rheum. 2007;56:4055–4064. doi: 10.1002/art.23056.
  28. Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane database of systematic reviews. 2014;2(2):CD005117. doi: 10.1002/14651858.CD005117.pub3.
  29. Milenkovic M, Djordievic М. AB0991 Efficiency of the intraarticular application of hyaluronic acid in the treatment of secondary osteoarthritis of the knee in patients with rheumatoid arthritis and in patients with primary osteoarthritis. Ann Rheum Dis. 2012;71(3):695. doi: 10.1136/annrheumdis-2012-eular.991.

Supplementary files

There are no supplementary files to display.

Views

Abstract - 67

PDF (Russian) - 10

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies